Raymond James Analyst: 'Optimistic About Data' From Pfizer, Moderna

Author:
Publish date:
Video Duration:
6:32

Coronavirus vaccines are--understandably--being covered heavily in the media right now. From the timeline to which company will seek the emergency use authorization from the Food & Drug Administration first. 

Steven Seedhouse, biotech analyst with Raymond James, joined TheStreet to talk about a vaccine timeline, the effectiveness of a vaccine and his thoughts on the top vaccine candidates.

Johnson & Johnson Vaccine Candidate

Johnson & Johnson just moved into Phase 3 of its trial.

Johnson & Johnson's vaccine candidate will be a single-shot dose.

The vaccine candidate, according to the National Institute of Health, is a "recombinant vector vaccine that uses a human adenovirus to express the SARS-CoV-2 spike protein in cells. Adenoviruses are a group of viruses that cause the common cold."

The company also reiterated its aim of producing and supplying more than one billion doses of the vaccine -- should it be approved by regulators -- through the course of 2021, and aims to have a decision on the vaccine's effectiveness either later this year or in the first months of the next.

The U.S. government has purchased 100 million doses of the vaccine, with the option to buy 200 million more if the vaccine gets approval.

More: Why Jim Cramer Is Still Bullish on Johnson & Johnson's Vaccine

Moderna Vaccine Candidate

Moderna's vaccine candidate would rely on being given in two doses. It is an mRNA vaccine, meaning that it uses messenger RNA, which is genetic material that carries information about a viral protein, and this is delivered to cells who are producing the protein and then trains the immune system to recognize it. 

It has a deal with the U.S. government through Operation Warp Speed to sell 100 million doses of its candidate--if it gets an EUA from the FDA--to the U.S. 

More: Jim Cramer Says Moderna Could Be Among Winners in Vaccine Race 

AstraZeneca Vaccine Candidate

AstraZeneca's U.S. vaccine candidate trials have been put on hold due to a possible adverse reaction in a patient from one of its U.K. trials. Its U.K. trial has resumed. 

This candidate is also being given in two doses. This differs from Moderna's vaccine because uses a non-replicating adenovirus found in chimpanzees to deliver a SARS-CoV-2 protein which would induce an immune response.

AstraZeneca has an agreement to with the government to produce and deliver 300 million doses of the vaccine candidate.

Pfizer Vaccine Candidate

Like the others, this would be administered in two doses, and is also an mRNA vaccine. 

Pfizer has an agreement with Operation Warp Speed for 100 million doses if the vaccine candidate receives an EUA. Pfizer could be tapped for 500 million more doses if it gets approval.

So, what does Seedhouse think of the candidates? Watch the video above. 

You can follow Katherine Ross on Twitter at @byKatherineRoss.

Read more from Katherine Ross here.

Latest Videos From TheStreet and Jim Cramer: